Clearside posts Q4 net loss $7.3M; cash to Q4 2025; FDA aligns on CLS-AX Phase 3 in wet AMD

Clearside Biomedical, Inc.

Q4 2024 net loss $7.3M ($0.10/sh) vs $4.8M ($0.08) in Q4 2023; FY loss $34.4M ($0.47) vs $32.5M ($0.53).
Cash $20.0M at Dec 31, 2024; expected to fund operations into Q4 2025.
FDA alignment on Phase 3 for CLS-AX in wet AMD: two non-inferiority trials, sham control, after positive Phase 2b.
Partner Arctic Vision NDA for ARCATUS (XIPERE) in uveitic macular edema accepted in China; also approved in Australia and Singapore.
Tony Gibney appointed Chair of Board effective November 1, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.